Tango Therapeutics, Inc.
TNGXHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeTango Therapeutics, Inc., a precision oncology company, focuses on the discovery and development of drugs in defined patient populations with unmet medical need. Valued at $3.74B, TNGX is a mid-cap name in its sector. The company develops methylthioadenosine -cooperative protein arginine methyltransferase 5 (PRMT5) inhibitors, including TNG462, which is in Phase 1/2 clinical trial for treating pancreatic and lung cancer; and TNG456, a brain-penetrant PRMT5 inhibitor for the treatment of glioblastoma.
Market Cap
$3.74B
Beta
1.17
P/E (TTM)
—
P/E (Fwd)
-13.17
EPS (TTM)
$-0.85
EPS (Fwd)
$-1.69
ROE
-21.3%
ROA
-13.0%
Cash
$1.01B
Total Debt
$32.0M
Free CF
-$71.9M
52W Change
185.7%
Annual Financials
Cash vs Debt
Where TNGX stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, TNGX finished 4.89% below its 150-day moving average ($24.74) and 8.28% above its 200-day moving average ($21.73). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is TNGX overbought or oversold?
At the October 20, 2026 close, TNGX's RSI(14) was 45.8, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $1.01B in cash and $32.0M in debt, TNGX maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. Free cash flow is running at -$71.9M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -21.3% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has grown from $24.9M (2022) to $62.4M (2025), reflecting a 151% increase over the period.
The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. No single metric tells the full story. Reviewing TNGX's risk profile alongside its fundamentals and technical indicators provides a more complete picture.